Glucose-Responsive Vesicle Compositions for Automated Insulin Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly Type I and Type II, require frequent insulin injections and continuous blood glucose monitoring, which are cumbersome, costly, and prone to errors in dosing and timing.
Innovation Solution
Development of vesicle compositions containing insulin encapsulated in liposomes with boronic acid derivatives and sugar conjugates that release insulin in response to increased glucose levels, eliminating the need for continuous monitoring and manual insulin administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional insulin injection methods are used, then insulin can be delivered to patients, but the treatment requires frequent manual injections and continuous blood glucose monitoring which increases device complexity and patient burden
Solution Approach 1:
The liposome system performs self-service by automatically sensing glucose levels and releasing insulin without external intervention. The boronic acid-sugar crosslinks spontaneously form and break in response to glucose concentration changes, enabling the system to self-regulate insulin delivery based on physiological conditions.
Solution Approach 2:
The invention merges multiple functions into a single integrated system: glucose sensing, insulin storage, and controlled release are all combined within the liposome structure. This eliminates the need for separate monitoring devices and injection mechanisms, reducing overall system complexity.
2Measurement precision
If continuous blood glucose monitoring is implemented, then glucose levels can be tracked, but the cost and frequency of monitoring increase
Solution Approach 1:
The liposome system eliminates the need for external monitoring by incorporating intrinsic glucose sensing capability. The boronic acid moieties continuously sense glucose levels in real-time through spontaneous crosslinking reactions, providing ongoing measurement without requiring patient action or external devices.
Solution Approach 2:
The system provides continuous glucose sensing and insulin release rather than periodic measurements. The dynamic equilibrium of boronic acid-sugar crosslinks continuously responds to glucose concentration changes, maintaining constant surveillance and adjustment of insulin delivery.
3Reliability
If manual insulin injection is used, then insulin dosing can be controlled, but dosing errors and timing issues occur
Solution Approach 1:
The liposome system eliminates human error in dosing by autonomously regulating insulin release. The glucose-responsive crosslinking mechanism automatically adjusts insulin delivery based on real-time glucose levels, ensuring accurate dosing without requiring patient judgment or action.
Solution Approach 2:
The system implements negative feedback control where glucose sensing through boronic acid crosslinks provides continuous information about glucose levels, which automatically regulates insulin release. When glucose increases, crosslinks break and insulin is released; when glucose decreases, crosslinks reform and release stops, maintaining homeostasis.
4Extent of automation
If glucose-sensitive crosslinking is used, then insulin release can be triggered by glucose levels, but the chemical sensing mechanism adds complexity to the composition
Solution Approach 1:
The system exploits changes in chemical parameters (pH, glucose concentration) to trigger insulin release. The boronic acid-sugar crosslinking equilibrium shifts in response to glucose concentration changes, automatically controlling liposome stability and insulin release without requiring complex mechanical or electronic components.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vesicle compositions provide controlled insulin release in response to hyperglycemia, maintaining normoglycemic levels for extended periods without the need for frequent patient intervention, reducing the burden of traditional treatment methods.
Implementation Method 1
a DSPE-PEG-boronic acid derivative conjugate, wherein the first liposome composition encapsulates insulin
Implementation Method 2
exhibiting cross-linkages capable of cleavage by glucose
Data Source
Figure 1~2
Figure 3
Figure 4A~4D
AI summary
Vesicle compositions are provided that comprise a therapeutic compound. The vesicle compositions may be capable of releasing the therapeutic compound in response to the presence of an external trigger. The vesicle compositions may comprise a plurality of biocompatible vesicles. The biocompatible vesicles may comprise a therapeutic compound for treatment of a patient in need thereof, and one or more cross-linkages between two or more of the biocompatible vesicles, each cross-linkage comprising a chemical sensing moiety and a sensed moiety. In some embodiments, the therapeutic compound may be any compound that provides palliative, curative, or otherwise beneficial effects to a patent.